Statista, a global data company that publishes insights for 170 industries, projects four cancer therapies will be among the top 10 best-selling pharmaceutical products in the U.S. this year.  The ...

Neuroscientists at King's College London have pinpointed a mechanism behind the increased neural connectivity observed in the very early stages of Alzheimer's disease. Published in Translational ...

Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for ...

Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer.

When Dr Samson Magesa walked away from the busy wards of Mwananyamala Hospital a decade ago, he carried with him the frustrations of a medical professional who had witnessed too many patients ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...

Lots of people are talking about peptides. But what are they? Here’s a quick primer on the health trend and what we know about peptides’ safety.

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

Methionine restriction (MR) has shown significant promise in cancer therapy because it targets the unique methionine dependency of many tumors. However, despite extensive research on MR, a clear ...

Voluntary MFN commitments by 16 manufacturers reportedly cover ~70% of Medicare drug spending, potentially obviating GUARD/GLOBE finalization while avoiding predictable legal challenges. Lindsay ...

Colorectal cancer is one of the cancers where, if found early, it has a 91% chance of survival for the patient. If you find ...